More often than as a single agent, venetoclax is prescribed in combination with a monoclonal antibody.

How Do Monoclonal Antibodies Work? 

Monoclonal antibody treatments (mAbs) kill CLL cells by binding to the CD20 protein on their surface. This signals the body's immune system to target and destroy these cancer cells. However, this process may also affect healthy B-cells.

These treatments are administered by intravenous infusion. 

The two monoclonal antibodies that are FDA-approved for CLL treatment are obinutuzumab and rituximab.